Table III.

Proportion of APB-positive cells after siRNA treatment

Cell lines siRNA treatmenta APB+/SV40T−b (%) 
IIICF-T/B3 SV40T + C 98/170 (57.6) 
IIICF-402DE/D2 SV40T + C 20/176 (11.4) 
IIICF-T/B3 SV40T + p21-7 43/172 (25.0) 
IIICF-402DE/D2 SV40T + p21-7 18/179 (10.1) 
JFCF-6/T.1J/1D SV40T + C 85/137 (62.0) 
JFCF-6/T.1J/1D SV40T + p21-6 36/132 (27.3) 
IIICF-T/B3 SV40T + C 87/156 (55.8) 
IIICF-T/B3 SV40T + p21-6 34/158 (21.5) 
IIICF-T/B3 SV40T + p21-7 38/151 (25.2) 
IIICF-T/B3 SV40T + p53-9 29/153 (19.0) 
IIICF-T/B3 SV40T + p53-p 38/160 (23.8) 
IIICF-T/B3 SV40T + PCNA-1 81/154 (52.6) 
IIICF-T/B3 SV40T + PCNA-6 82/149 (55.0) 
Cell lines siRNA treatmenta APB+/SV40T−b (%) 
IIICF-T/B3 SV40T + C 98/170 (57.6) 
IIICF-402DE/D2 SV40T + C 20/176 (11.4) 
IIICF-T/B3 SV40T + p21-7 43/172 (25.0) 
IIICF-402DE/D2 SV40T + p21-7 18/179 (10.1) 
JFCF-6/T.1J/1D SV40T + C 85/137 (62.0) 
JFCF-6/T.1J/1D SV40T + p21-6 36/132 (27.3) 
IIICF-T/B3 SV40T + C 87/156 (55.8) 
IIICF-T/B3 SV40T + p21-6 34/158 (21.5) 
IIICF-T/B3 SV40T + p21-7 38/151 (25.2) 
IIICF-T/B3 SV40T + p53-9 29/153 (19.0) 
IIICF-T/B3 SV40T + p53-p 38/160 (23.8) 
IIICF-T/B3 SV40T + PCNA-1 81/154 (52.6) 
IIICF-T/B3 SV40T + PCNA-6 82/149 (55.0) 

C, nonsilencing control siRNA.

a

Cells were treated with 10 nM siRNA per target for 4 d before being fixed for immunostaining.

b

Only cells that were negative by immunostaining for SV40T were examined for APBs.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal